Clear Search sequence regions

  • albumin (4)
  • antitumor (3)
  • cell (4)
  • cremophor el (1)
  • egg yolk (1)
  • humans (1)
  • lecithin (3)
  • male (1)
  • mice (2)
  • phospholipid (1)
  • podophyllotoxin (1)
  • rats (1)
  • rats wistar (1)
  • vm 26 (4)
  • xenograft (1)
  • Sizes of these terms reflect their relevance to your search.

    Teniposide (VM-26) is a semisynthetic derivative of podophyllotoxin effective for the treatment of many types of tumors. However, the poor water solubility and adverse effects restrict its clinical use. Our study aimed to develop a novel phospholipid complex albumin nanoparticle (VM-E80-AN) to reduce the systemic toxicity and enhance antitumor activity of VM-26. Egg yolk lecithin E80 and human serum albumin (HSA) were used as the main excipients to replace Cremophor EL in the commercial formulation. The physicochemical properties of VM-E80-AN were characterized to optimize the formulation. Cell and animal studies were further carried out to estimate its tumor inhibition efficacy, biodistribution, and toxicity. Comparison between VM-26 solution and VM-E80-AN showed that VM-E80-AN significantly reduced the toxicity of VM-26 and enhanced the anticancer efficacy of the drug. Thus, VM-E80-AN represents a safe and promising formulation of teniposide for clinical application. Copyright © 2015 Elsevier B.V. All rights reserved.


    Xinyi He, Nanxi Xiang, Jinjie Zhang, Jing Zhou, Yao Fu, Tao Gong, Zhirong Zhang. Encapsulation of teniposide into albumin nanoparticles with greatly lowered toxicity and enhanced antitumor activity. International journal of pharmaceutics. 2015 Jun 20;487(1-2):250-9

    Expand section icon Mesh Tags

    Expand section icon Substances

    PMID: 25899285

    View Full Text